Jinling Pharmaceutical has added two products, compound sulfamethoxazole injection and cefixime granules, to the National Essential Medicines List 2026 edition, which takes effect on September 1, 2026. Existing products such as ferrous succinate tablets and Mailuoning injection remain on the list, with no products removed. The company stated that this inclusion will help expand coverage of the relevant products in the primary healthcare market and have a positive impact on future market expansion. In the first quarter of 2026, Jinling Pharmaceutical achieved revenue of 769 million yuan and net profit attributable to the parent of 28 million yuan.
Jinling Pharmaceutical Co LtdTwo products added to National Essential Medicines List, expanding market coverage.